Targets › GLS
2 programs from 2 companies in 6 trials: 5 Phase 1, 1 Phase 2; Oncology, Infectious disease; next expected readout Nov 2026.
Catalyzes the first reaction in the primary pathway for the renal catabolism of glutamine. Plays a role in maintaining acid-base homeostasis. (UniProt, O94925)
Open in Phaseline: the race on GLS, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Telaglenastat Glutaminase kidney isoform, mitochondrial inhibitor | GLS | Phase 2 | Advanced Malignant Solid Neoplasm; Leptomeningeal Neoplasm; Advanced Lung Non-Small Cell Carcinoma; Recurrent Multiple Myeloma … | Nov 2026 |
| Douglas Postels, MD, MS | 6-diazo-5-oxo-L-norleucine (DON) Glutaminase inhibitor; inhibits de novo nucleotide synthesis via glutamine antagonism | GLS | Phase 1 | Malaria, Cerebral | Nov 2028 |
Advanced Malignant Solid Neoplasm (1) Leptomeningeal Neoplasm (1) Advanced Lung Non-Small Cell Carcinoma (1) Recurrent Multiple Myeloma (1) Astrocytoma, IDH-Mutant, Grade 2 (1) Malaria, Cerebral (1)
protein or peptide (1), small molecule (1)
National Cancer Institute (NCI) (1) Douglas Postels, MD, MS (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.